GlassScriptPhysician profile
Jennifer A Lash
NPI 1831227784
$3,856.72
in general payments reported to CMS, 2019-2025
33 companies · $830 in 2025
The $830 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $123 · 2021: $427 · 2022: $662 · 2023: $850 · 2024: $612 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,291.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $851.29 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $736.33 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $399.10 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $238.92 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.61 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $155.46 | 2021-2023 | Verquvo |
| Medtronic, INC. | $146.22 | 2025 | Simulus |
| Actelion Pharmaceuticals US, INC. | $143.04 | 2025 | Uptravi, Opsumit |
| Novo Nordisk INC | $140.94 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $98.67 | 2019-2020 | |
| Irhythm Technologies, INC. | $73.78 | 2022-2024 | Zio Monitor, Zio Xt Patch |
| Sanofi-Aventis U.S. LLC | $69.85 | 2019-2021 | |
| Amgen INC. | $64.50 | 2023-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $55.25 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $51.43 | 2020-2023 | Farxiga |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $49.81 | 2024-2025 | Bodyguardian |
| Bayer Healthcare Pharmaceuticals INC. | $43.49 | 2021-2022 | |
| Heartflow, INC. | $38.93 | 2025 | |
| Alnylam Pharmaceuticals INC. | $30.61 | 2025 | Onpattro |
| Kowa Pharmaceuticals America, INC. | $27.14 | 2020-2021 | |
| Kestra Medical Technology Services, INC. | $25.33 | 2025 | Assure Wcd |
| Vital Connect, INC | $21.06 | 2024 | Vitalpatch Rtm |
| Abiomed | $19.89 | 2025 | |
| Bridgebio Pharma, INC. | $18.29 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, LTD. | $17.84 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.42 | 2023 | Evkeeza |
| Atricure, INC. | $15.38 | 2024 | |
| Genzyme Corporation | $14.73 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.04 | 2025 | Edarbi |
| Lantheus Medical Imaging, INC. | $12.98 | 2020 | |
| Amarin Pharma, INC. | $12.62 | 2019 | |
| Preventice Services, LLC | $11.63 | 2020 | |
| Lifescan, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Lash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.